Steven Paul is our President and CEO, a member of the board of directors and a Venture Partner at Third Rock Ventures. Dr. Paul brings to Voyager more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. As venture partner Third Rock, he helps lead the ideation and development of new companies, including Voyager. Before joining Voyager, Dr. Paul was the Founding Director of the Appel Alzheimer’s Disease Research Institute, where he was the Principal Investigator of the Institute’s novel adeno-associated virus (AAV) gene therapy program for Alzheimer’s disease, as well as professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of Discovery Research and Neuroscience Research. As President of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul has authored or co-authored more than 500 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Paul currently serves on the board of Sage Therapeutics and Alnylam Pharmaceuticals, and is a chairman of the board for the Foundation for the National Institutes of Health. He previously served on the board of the Sigma Aldrich company, which was acquired by Merck KGaA.

science